Last reviewed · How we verify
NCT03748524
Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine
EARLY_PHASE1 trial testing Influenza Vaccine in Immunity, Cellular in 11 participants. Completed in 20 June 2022.
30 September 2021
Quick facts
| Lead sponsor | Washington University School of Medicine |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 11 |
| Start date | 29 October 2018 |
| Primary completion | 30 September 2021 |
| Estimated completion | 20 June 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Influenza Vaccine — full drug profile →
Conditions studied
- Immunity, Cellular — all drugs for Immunity, Cellular →
Sponsor
Washington University School of Medicine
Who can join
Adults 18 to 50, any sex, with Immunity, Cellular. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Immunization with the inactivated influenza vaccine with blood samples collected at 7 visits (baseline, day 7, 14, 28, 60, 90 and 180, fine needle aspiration (FNAs) from axillary lymph nodes at baseline, days, 4, 14, 28, 60 and 180. BMA at baseline, days 28 and 180.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03748524
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Influenza Vaccine
Trials testing the same drug.
- NCT06864143 — A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in A · Phase 2 · completed
- NCT06097273 — A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age · Phase 3 · completed
- NCT05519839 — A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine · Phase 2 · completed
- NCT05074303 — Beta-glucan and Immune Response to Influenza Vaccine · Phase 2 · completed
- NCT05294588 — Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae · Phase 2 · completed
Other Washington University School of Medicine trials
Trials by the same sponsor.
- NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
- NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
- NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
- NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03748524 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
- Last refreshed: 13 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03748524.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing